|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Flutamide-metformin plus an oral contraceptive (OC) for young women with |
| polycystic ovary syndrome: switch from third- to fourth-generation OC |
| Human Reproduction. 2004;19(8):1725-1727. |
| Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young |
| women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS). We verified |
| whether the lipolytic efficacy of flutamide-metformin in women with PCOS is enhanced by giving an oral contraceptive |
| (OC) co-therapy that contains drospirenone, instead of gestodene, as progestin. An open-labelled study was carried |
| out in which non-obese women with PCOS (n = 29; age -20 years), who had been on a combination of flutamide (62.5 |
| mg/day), metformin (850 mg/day) and ethinylestradiol-gestodene for 8-15 months, were randomized for replacement |
| of the gestodene OC by a drospirenone OC. Assessments of endocrine-metabolic state and body composition (by |
| dual-energy X-ray absorptiometry) were performed at randomization and after 6 months. The switch to drospirenone |
| OC was accompanied by a reduction of total and abdominal fat (mean -0.8 and -0.5 kg) and by an increment of lean |
| body mass (10.6 kg; all P < 0.01), so that body adiposity was strikingly reduced without changing body weight. In |
| nonobese women with PCOS, low-dose flutamide-metformin reduces total and abdominal fat excess more effectively |
| if contraceptive co-therapy contains drospirenone, instead of gestodene, as progestin. (PubHealth.info Document ID: |
| PubHealth.info NOTE: The author(s) of this article titled, "Flutamide-metformin plus an oral contraceptive (OC) for |
| young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.", |
| is(are) Ibáñez L; de Zegher F. The source of this article is "Human Reproduction. 2004;19(8):1725-1727.". This |
| article was published in 2004 in English language(s). (PubHealth.info® Document ID: CONT1T 562-06. All rights |
| reserved with PubHealth.info) PIN: 562 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
